SPECIALTY GUIDELINE MANAGEMENT

OCREVUS (ocrelizumab) OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

- A. Treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsingremitting disease, and active secondary progressive disease, in adults.
- B. Treatment of primary progressive MS, in adults.

All other indications are considered experimental/investigational and not medically necessary.

II. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a neurologist.

III. CRITERIA FOR INITIAL APPROVAL

A. Relapsing Forms of Multiple Sclerosis

Authorization of 12 months may be granted to members who have been diagnosed with a relapsing form of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapse).

B. Clinically Isolated Syndrome

Authorization of 12 months may be granted to members for treatment of clinically isolated syndrome of multiple sclerosis.

C. Primary Progressive Multiple Sclerosis

Authorization of 12 months may be granted to members for treatment of primary progressive multiple sclerosis.

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for members with an indication listed in Section III who are experiencing disease stability or improvement while receiving the requested drug.

V. OTHER CRITERIA

Ocrevus-Ocrevus Zunovo 1707-A SGM P2024a.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number(s) 1707-A

- A. Members will not use the requested drug concomitantly with other disease modifying multiple sclerosis agents (Note: Ampyra and Nuedexta are not disease modifying).
- B. Authorization may be granted for pediatric members less than 18 years of age when benefits outweigh risks.

VI. REFERENCES

- 1. Ocrevus [package insert]. South San Francisco, CA: Genentech, Inc.; June 2024.
- 2. Ocrevus Zunovo [package insert]. South San Francisco, CA: Genentech, Inc.; September 2024.

Ocrevus-Ocrevus Zunovo 1707-A SGM P2024a.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of